Outlook Therapeutics
OTLK
76 hedge funds and large institutions have $29.8M invested in Outlook Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 9 closing their positions.
412% more capital inflows, than outflows
Capital inflows: $4.47M | Capital outflows: $874K
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
1.53% more ownership
Funds ownership: 10.66% → 12.19% (+1.5%)
1% less funds holding
Funds holding: 77 → 76 (-1)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$3.62M |
| 2 |
BlackRock
New York
|
+$206K |
| 3 |
GSA Capital Partners
London,
United Kingdom
|
+$120K |
| 4 |
Goldman Sachs
New York
|
+$101K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$60.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$164K |
| 2 |
Two Sigma Advisers
New York
|
-$160K |
| 3 |
Vista Finance
Clayton,
Missouri
|
-$130K |
| 4 |
Renaissance Technologies
New York
|
-$61K |
| 5 |
Graypoint LLC
Albany,
New York
|
-$46K |
OTLK Hedge Fund Activity: Q4 2022 in Review
76 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2022, worth a combined $29.8M — up 1.2% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of OTLK and 6 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 24 added.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.62M. The largest seller was Fidelity Investments, cutting an estimated $164K.
- 76 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2022, down from 77 in Q3 2022.
- Funds reported $29.8M of Outlook Therapeutics stock for Q4 2022, up 1.2% quarter-over-quarter.
- 6 funds opened new Outlook Therapeutics positions in Q4 2022 and 9 closed out, a net change of -3 holders.
- The largest Outlook Therapeutics buyer in Q4 2022 was Altium Capital Management, an estimated $3.62M added.
- The largest Outlook Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $164K sold.
Based on aggregated 13F filings for Q4 2022.